 | |
| Clinical data | |
|---|---|
| AHFS/ Drugs.com | International Drug Names |
|
Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.220.132 |
| Chemical and physical data | |
| Formula | C23H33NO7S2 |
| Molar mass | 499.64 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Suplatast tosilate ( INN) is an inhibitor of cytokine T helper cells. [1] Overstimulation of these Th2 cells can lead to an allergic reaction, [2] so the drug is used as an antihistamine. [3] It has also been used in the treatment of Kimura's disease. [4] [5]
Acylation of 1-(4-aminophenoxy)-3-ethoxypropan-2-ol (1) with 3-methylthiopropionyl chloride (2) gives the amide (3). Methylation of the thioether using methyl tosylate (4) yields suplatast as its toluenesulfonic acid salt. [6] [7] [8]
- ^ Tamaoki J, Kondo M, Sakai N, et al. (July 2000). "Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group". Lancet. 356 (9226): 273–8. doi: 10.1016/S0140-6736(00)02501-0. PMID 11071181. S2CID 25482487.
- ^ Zhu J, Paul WE (September 2008). "CD4 T cells: fates, functions, and faults". Blood. 112 (5): 1557–1569. doi: 10.1182/blood-2008-05-078154. PMC 2518872. PMID 18725574.
- ^ Taniguchi H, Togawa M, Ohwada K, et al. (December 1996). "Suplatast tosilate, a new type of antiallergic agent, prevents the expression of airway hyperresponsiveness in guinea pigs". European Journal of Pharmacology. 318 (2–3): 447–54. doi: 10.1016/S0014-2999(96)00810-2. PMID 9016937.
- ^ Ueda T, Arai S, Amoh Y, Katsuoka K (2011). "Kimura's disease treated with suplatast tosilate and loratadine". European Journal of Dermatology. 21 (6): 1020–1. doi: 10.1684/ejd.2011.1539. PMID 21914581.
- ^ Tsukagoshi H, Nagashima M, Horie T, et al. (December 1998). "Kimura's disease associated with bronchial asthma presenting eosinophilia and hyperimmunoglobulinemia E which were attenuated by suplatast tosilate (IPD-1151T)". Internal Medicine. 37 (12): 1064–7. doi: 10.2169/internalmedicine.37.1064. PMID 9932643.
- ^ US patent 4556737, Akihide Koda, et al., "Sulfonium compounds, processes for preparing the compounds and pharmacological composiitons containing the same", issued 1985-12-03, assigned to Taiho Pharmaceutical Co Ltd
- ^ "Suplatast tosilate". Thieme. Retrieved 2024-07-03.
- ^ "Suplatast tosilate". chemdrug.com. Retrieved 2024-07-03.
- Sano Y (December 1996). "[Anti-inflammatory drugs for the treatment of bronchial hyperresponsiveness]". Nihon Kyōbu Shikkan Gakkai Zasshi (in Japanese). 34 Suppl: 48–53. PMID 9216184.
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
|
| |
| Clinical data | |
|---|---|
| AHFS/ Drugs.com | International Drug Names |
|
Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.220.132 |
| Chemical and physical data | |
| Formula | C23H33NO7S2 |
| Molar mass | 499.64 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Suplatast tosilate ( INN) is an inhibitor of cytokine T helper cells. [1] Overstimulation of these Th2 cells can lead to an allergic reaction, [2] so the drug is used as an antihistamine. [3] It has also been used in the treatment of Kimura's disease. [4] [5]
Acylation of 1-(4-aminophenoxy)-3-ethoxypropan-2-ol (1) with 3-methylthiopropionyl chloride (2) gives the amide (3). Methylation of the thioether using methyl tosylate (4) yields suplatast as its toluenesulfonic acid salt. [6] [7] [8]
- ^ Tamaoki J, Kondo M, Sakai N, et al. (July 2000). "Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group". Lancet. 356 (9226): 273–8. doi: 10.1016/S0140-6736(00)02501-0. PMID 11071181. S2CID 25482487.
- ^ Zhu J, Paul WE (September 2008). "CD4 T cells: fates, functions, and faults". Blood. 112 (5): 1557–1569. doi: 10.1182/blood-2008-05-078154. PMC 2518872. PMID 18725574.
- ^ Taniguchi H, Togawa M, Ohwada K, et al. (December 1996). "Suplatast tosilate, a new type of antiallergic agent, prevents the expression of airway hyperresponsiveness in guinea pigs". European Journal of Pharmacology. 318 (2–3): 447–54. doi: 10.1016/S0014-2999(96)00810-2. PMID 9016937.
- ^ Ueda T, Arai S, Amoh Y, Katsuoka K (2011). "Kimura's disease treated with suplatast tosilate and loratadine". European Journal of Dermatology. 21 (6): 1020–1. doi: 10.1684/ejd.2011.1539. PMID 21914581.
- ^ Tsukagoshi H, Nagashima M, Horie T, et al. (December 1998). "Kimura's disease associated with bronchial asthma presenting eosinophilia and hyperimmunoglobulinemia E which were attenuated by suplatast tosilate (IPD-1151T)". Internal Medicine. 37 (12): 1064–7. doi: 10.2169/internalmedicine.37.1064. PMID 9932643.
- ^ US patent 4556737, Akihide Koda, et al., "Sulfonium compounds, processes for preparing the compounds and pharmacological composiitons containing the same", issued 1985-12-03, assigned to Taiho Pharmaceutical Co Ltd
- ^ "Suplatast tosilate". Thieme. Retrieved 2024-07-03.
- ^ "Suplatast tosilate". chemdrug.com. Retrieved 2024-07-03.
- Sano Y (December 1996). "[Anti-inflammatory drugs for the treatment of bronchial hyperresponsiveness]". Nihon Kyōbu Shikkan Gakkai Zasshi (in Japanese). 34 Suppl: 48–53. PMID 9216184.
|
| This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |